Literature DB >> 9648597

Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors.

A Zelmanowicz1, A Hildesheim, M E Sherman, S R Sturgeon, R J Kurman, R J Barrett, M L Berman, R Mortel, L B Twiggs, G D Wilbanks, L A Brinton.   

Abstract

OBJECTIVE: To elucidate factors linked to the development of malignant mixed mullerian tumors (MMMT) and determine whether the risk factor profile for these tumors corresponds with that for the more common endometrial carcinomas.
METHODS: A multicenter case-control study of 424 women diagnosed with endometrial carcinoma, 29 women diagnosed with MMMT, and 320 community controls was conducted. Review of pathological reports and slides was performed to classify cases by histological type. All participants were asked to respond to a questionnaire which ascertained information on exposure to factors postulated to be linked to the development of uterine tumors.
RESULTS: Women with endometrial carcinomas and MMMTs were similar with respect to age and educational attainment. Women diagnosed with MMMTs were more likely than those diagnosed with carcinomas to be of African-American descent (28% vs 4%; P = 0.001). Weight, exogenous estrogen use, and nulliparity were related to risk of both tumor types. Marked obesity was associated with a 4.8-fold (95% CI = 3.0,7.6) increase in risk of carcinoma and a 3.2-fold (95% CI = 1.1,9.1) increase in risk of MMMT development. Use of exogenous estrogens increased the odds of developing carcinomas by 2-fold (95% CI = 1.3,3.2) and that of developing MMMTs by 1.8-fold (95% CI = 0.57,5.5). Nulliparity was associated with a 2.9-fold (95% CI = 1.9,4.8) increase in risk of carcinomas and a 1.7-fold (95% CI = 0.53,5.6) increase in risk of MMMTs. Oral contraceptive use protected against the development of both carcinomas (OR = 0.39; 95% CI = 0.26,0.58) and MMMTs (OR = 0.76; 95% CI = 0.25,2.3). Current smokers were at a reduced risk of developing endometrial carcinomas (OR = 0.34; 95% CI = 0.21,0.55) and MMMTs (OR = 0.57; 95% CI = 0.15,2.3), while former smokers were at an increased risk of MMMT (OR = 2.7; 95% CI = 1.1,6.8) but not carcinoma development (OR = 0.81; 95% CI = 0.56,1.2).
CONCLUSION: Results from this study suggest that MMMTs and carcinomas have a similar risk factor profile. This observation is compatible with the hypothesis that the pathogenesis of these two histological types of uterine tumors is similar.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648597     DOI: 10.1006/gyno.1998.4941

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  24 in total

1.  Metachronous small bowel metastasis from a mixed Müllerian mesodermal tumour.

Authors:  J M L Williamson; M Stevens; D Mahon
Journal:  Ann R Coll Surg Engl       Date:  2016-01-07       Impact factor: 1.891

Review 2.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

3.  Which is worse: uterine papillary serous carcinomas or carcinosarcomas?

Authors:  Taejong Song; Chel Hun Choi; Yoo-Young Lee; Tae-Joong Kim; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

Review 4.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

Authors:  Khadra Galaal; Esther van der Heijden; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant; Nagindra Das; Alberto D Lopes
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

5.  Relationships of uterine and ovarian tumors to pre-existing chronic conditions.

Authors:  Louise A Brinton; Lori C Sakoda; Kirsten Frederiksen; Mark E Sherman; Susanne K Kjaer; Barry I Graubard; Jorgen H Olsen; Lene Mellemkjaer
Journal:  Gynecol Oncol       Date:  2007-09-07       Impact factor: 5.482

6.  Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

Authors:  Louise A Brinton; Ashley S Felix; D Scott McMeekin; William T Creasman; Mark E Sherman; David Mutch; David E Cohn; Joan L Walker; Richard G Moore; Levi S Downs; Robert A Soslow; Richard Zaino
Journal:  Gynecol Oncol       Date:  2013-02-26       Impact factor: 5.482

7.  URI1 amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis.

Authors:  Yu Wang; Michael J Garabedian; Susan K Logan
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

Review 8.  Uterine sarcoma 2008.

Authors:  Jeff F Lin; Brian M Slomovitz
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

9.  Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma.

Authors:  Eric J Devor; Jillian N DE Mik; Shyam Ramachandran; Michael J Goodheart; Kimberly K Leslie
Journal:  Exp Ther Med       Date:  2012-01-25       Impact factor: 2.447

Review 10.  Treatment of early uterine sarcomas: disentangling adjuvant modalities.

Authors:  Flora Zagouri; Athanasios-Meletios Dimopoulos; Stelios Fotiou; Vassilios Kouloulias; Christos A Papadimitriou
Journal:  World J Surg Oncol       Date:  2009-04-08       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.